The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1686
ISSUE1686
October 2, 2023
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
October 2, 2023 (Issue: 1686)
Delandistrogene moxeparvovec-rokl (Elevidys –
Sarepta), an adeno-associated virus (AAV) vector-based
gene therapy, has received accelerated
approval from the FDA for treatment of ambulatory
children 4-5 years old with Duchenne...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.